JAK2 and rheumatoid arthritis: The baseline risk of HZ in rheumatoid arthritis is 1.5–2-fold higher compared to the general population, and the incidence of HZ reported with tofacitinib, which preferentially inhibits JAK1, JAK2, and JAK3, is double that reported in RA (25).